CD19 and non-Hodgkin lymphoma: As the most studied and researched target for CAR therapy, CD19 has shown impressive success in clinical settings to treat Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin Lymphoma (NHL), and Chronic Lymphocytic Leukemia (CLL) [10].